P-072Pembrolizumab versus investigator’s choice single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma that progressed after first-line therapy: Phase 3 KEYNOTE-181 study

Toshihiko Doi,Jaafar Bennouna,Lin Shen,Peter Enzinger,Ruixue Wang,Rita Dalal,Minori Koshiji,Manish Shah

DOI: https://doi.org/10.1093/annonc/mdx261.071

IF: 51.769

2017-01-01

Annals of Oncology

Abstract:Introduction: The PD-1 ligand, PD-L1, is frequently overexpressed in esophageal cancer and this overexpression may be associated with poor prognosis. Pembrolizumab is a monoclonal antibody that allows antitumor autoimmune response by blocking the PD-1–ligand interaction. In the phase 1b KEYNOTE-028 trial, pembrolizumab demonstrated antitumor activity (objective response rate [ORR], 30%) and was well tolerated in patients with PD-L1–positive advanced esophageal cancer. The open-label, randomized, phase 3 KEYNOTE-181 trial (ClinicalTrials.gov, NCT02564263) was designed to compare the efficacy and safety of pembrolizumab versus single-agent chemotherapy in patients with previously treated advanced/metastatic (a/m) esophageal cancer. Methods: Key eligibility criteria included age ≥18 years, a/m adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ), measurable disease, documented progressive disease (PD) during/after first-line therapy, ECOG performance status 0-1, no active autoimmune disease or CNS metastases, life expectancy >3 months, and provision of a tissue sample for biomarker analysis. HER2 status must be determined for patients with EGJ adenocarcinoma; if HER2 positive, there must be documentation of PD while the patient was on trastuzumab-containing therapy. Eligible patients will be randomly assigned (unblinded) 1:1 to receive intravenous (IV) pembrolizumab 200 mg Q3W or investigator’s choice of paclitaxel 80-100 mg/m2 on days 1, 8, and 15 of each 4 week cycle, docetaxel 75 mg/m2 Q3W, or irinotecan 180 mg/m2 Q2W. Treatments will continue until documented PD, intolerable toxicity, patient/investigator decision to discontinue, or (for pembrolizumab) until 35 cycles (∼2 years). Adverse events (AEs) will be monitored throughout treatment and for 30 days thereafter (90 days for serious AEs). Tumor response will be assessed Q9W per RECIST v1.1 and adapted immune-related RECIST (irRECIST; blinded central imaging vendor review). All patients will be followed up Q9W for overall survival (OS) until death, withdrawal of consent, or end of study. Primary end points are progression-free survival (PFS) (per RECIST v1.1, blinded central imaging vendor review) and OS. Secondary end points include ORR (per RECIST v1.1, blinded central imaging vendor review) and safety. Approximately 600 patients will be enrolled. Results: Conclusion: